Page 469 - Read Online

Abbas et al. Hepatoma Res 2018;4:43 I http://dx.doi.org/10.20517/2394-5079.2018.26 Page 7 of 8

carcinoma development in non-cirrhotic patients with sustained virologic response for chronic hepatitis C virus infection. J
Gastroenterol Hepatol 2015;30:1183-9.
33. Kitab B, Ezzikouri S, Alaoui R, Nadir S, Badre W, Trepo C, Chemin I, Benjelloun S. Occult HBV infection in Morocco: from chronic
hepatitis to hepatocellular carcinoma. Liver Int 2014;34:e144-50.
34. K-Kutala B, Bedossa P, Guedj J, Asselah T, Martinot-Peignoux M, Duval X, Marcellin P. Patients with chronic hepatitis C without
advanced fibrosis and hepatocellular carcinoma: a retrospective clinical-pathological study. Dig Liver Dis 2015;47:296-302.
35. Huang YT, Yang HI, Liu J, Lee MH, Freeman JR, Chen CJ. Mediation analysis of hepatitis B and C in relation to hepatocellular
carcinoma risk. Epidemiology 2016;27:14-20.
36. Goh GB, Chang PE, Tan CK. Changing epidemiology of hepatocellular carcinoma in Asia. Best Pract Res Clin Gastroenterol
2015;29:919-28.
37. Kar P. Risk factors for hepatocellular carcinoma in India. J Clin Exp Hepatol 2014;4:S34-42.
38. Palliyaguru DL, Wu F. Global geographical overlap of aflatoxin and hepatitis C: controlling risk factors for liver cancer worldwide.
Food Addit Contam Part A Chem Anal Control Expo Risk Assess 2013;30:534-40.
39. Huang CM, Hu TH, Chang KC, Tseng PL, Lu SN, Chen CH, Wang JH, Lee CM, Tsai MC, Lin MT, Yen YH, Hung CH, Cho CL,
Wu CK. Dynamic noninvasive markers predict hepatocellular carcinoma in chronic hepatitis C patients without sustained virological
response after interferon-based therapy: prioritize who needs urgent direct-acting antiviral agents. Medicine (Baltimore) 2017;96:e8696.
40. Li DK, Ren Y, Fierer DS, Rutledge S, Shaikh OS, Lo Re V 3rd, Simon T, Abou-Samra AB, Chung RT, Butt AA. The short-term
incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: an ERCHIVES study.
Hepatology 2018;67:2244-53.
41. Innes H, Barclay ST, Hayes PC, Fraser A, Dillon JF, Stanley A, Bathgate A, McDonald SA, Goldberg D, Valerio H, Fox R(8), Kennedy N,
Bramley P, Hutchinson SJ. The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and sustained viral response: role
of the treatment regimen. J Hepatol 2017; doi: 10.1016/j.jhep.2017.10.033.
42. Chang KC, Ye YH, Wu CK, Lin MT, Tsai MC, Tseng PL, Hu TH. Risk factors for development of hepatocellular carcinoma in patients
with chronic hepatitis C without sustained response to combination therapy. J Formos Med Assos 2017; doi: 10.1016/j.jfma.2017.11.008.
43. Kanwal F, Kramer JR, Ilyas J, Duan Z, El-Serag HB. HCV genotype 3 is associated with an increased risk of cirrhosis and
hepatocellular cancer in a national sample of U.S. Veterans with HCV. Hepatology 2014;60:98-105.
44. Hedenstierna M, Nangarhari A, Weiland O, Aleman S. Diabetes and cirrhosis are risk factors for hepatocellular carcinoma after
successful treatment of chronic hepatitis C. Clin Infect Dis 2016;63:723-9.
45. Noh R, Lee DH, Kwon BW, Kim YH, Kim SB, Song IH. Clinical impact of viral load on the development of hepatocellular carcinoma
and liver-related mortality in patients with hepatitis C virus infection. Gastroenterol Res Pract 2016; doi: 10.1155/2016/7476231.
46. Baumert TF, Jühling F, Ono A, Hoshida Y. Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals. BMC
Med 2017;15:52.
47. El-Serag HB, Kanwal F, Richardson P, Kramer J. Risk of hepatocellular carcinoma after sustained virological response in Veterans with
hepatitis C virus infection. Hepatology 2016;64:130-7.
48. Janjua NZ, Chong M, Kuo M, Woods R, Wong J, Yoshida EM, Sherman M, Butt ZA, Samji H, Cook D, Yu A, Alvarez M, Tyndall M,
Krajden M. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada. J
Hepatol 2017;66:504-13.
49. Mattos AA, Marcon Pdos S, Araújo FS, Coral GP, Tovo CV. Hepatocellular carcinoma in a non-cirrhotic patient with sustained
virological response after hepatitis C treatment. Rev Inst Med Trop Sao Paulo 2015;57:519-22.
50. El-Shamy A, Shindo M, Shoji I, Deng L, Okuno T, Hotta H. Polymorphisms of the core, NS3, and NS5A proteins of hepatitis C virus
genotype 1b associate with development of hepatocellular carcinoma. Hepatology 2013;58:555-63.
51. Balasus D, Way M, Fusilli C, Mazza T, Morgan MY, Cervello M, Giannitrapani L, Soresi M, Agliastro R, Vinciguerra M, Montalto
G. The association of variants in PNPLA3 and GRP78 and the risk of developing hepatocellular carcinoma in an Italian population.
Oncotarget 2016;7:86791-802.
52. Fakhry AB, Ahmed AI, AbdelAlim MA, Ramadan DI. RECK gene promoter rs10814325 polymorphism in Egyptian patients with
hepatocellular carcinoma on top of chronic hepatitis C viral infection. Asian Pac J Cancer Prev 2016;17:2383-8.
53. ELBassuoni MA, Abd El Fatah G, Zaghla H. IL17A gene polymorphism, serum IL17 and total IgE in Egyptian population with chronic
HCV and hepatocellular carcinoma. Immunol Lett 2015;168:240-5.
54. Labib HA, Ahmed HS, Shalaby SM, Wahab EA, Hamed EF. Genetic polymorphism of IL-23R influences susceptibility to HCV-related
hepatocellular carcinoma. Cell Immunol 2015;294:21-4.
55. Radwan MI, Pasha HF, Mohamed RH, Hussien HI, El-Khshab MN. Influence of transforming growth factor-β1 and tumor necrosis
factor-α genes polymorphisms on the development of cirrhosis and hepatocellular carcinoma in chronic hepatitis C patients. Cytokine
2012;60:271-6.
56. Hsu CS, Huang CJ, Kao JH, Lin HH, Chao YC, Fan YC, Tsai PS. Interferon-based therapy decreases risks of hepatocellular carcinoma
and complications of cirrhosis in chronic hepatitis C patients. PLoS One 2013;8:e70458.
57. Moon C, Jung KS, Kim DY, Baatarkhuu O, Park JY, Kim BK, Kim SU, Ahn SH, Han KH. Lower incidence of hepatocellular carcinoma
and cirrhosis in hepatitis C patients with sustained virological response by pegylated interferon and ribavirin. Dig Dis Sci 2015;60:573-81.
58. Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis C virus infection and the development of
hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med 2013;158:329-37.
59. Harada N, Hiramatsu N, Oze T, Morishita N, Yamada R, Hikita H, Miyazaki M, Yakushijin T, Miyagi T, Yoshida Y, Tatsumi T, Kanto T,